Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Kyoto University Pfizer Astellas Pharma Inc |
---|---|
Information provided by: | Kyoto University |
ClinicalTrials.gov Identifier: | NCT00304772 |
The purpose of this study is to verify the equivalence in clinical efficacy of fluconazole and micafungin for the treatment of Candida bloodstream infection in non-neutropenic patients.
Condition | Intervention | Phase |
---|---|---|
Candidiasis Sepsis |
Drug: Fluconazole Drug: Micafungin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Single Blind (Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized Comparative Study of Fluconazole Versus Micafungin for the Treatment of Candida Bloodstream Infection in Non-Neutropenic Patients |
Estimated Enrollment: | 190 |
Study Start Date: | August 2006 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: Fluconazole
400mg/day
|
2: Active Comparator |
Drug: Micafungin
150mg/day
|
Candida bloodstream infection occurs in patients with poor general conditions and has poor prognosis with attributable mortality of more than 30%. Clinical efficacy of fluconazole for the treatment of Candida bloodstream infection has been reported in clinical studies, since 1985 when it placed on the market. Fluconazole has established a position as the first-line drug up to date. However, possibly associated with the increased use of fluconazole, increased frequency of Candida species or strains with low susceptibility to fluconazole has been pointed out. Micafungin, an antifungal echinocandin with a different antifungal mechanism from fluconazole, has been reported to show good in vitro activity to various Candida species and strains with fluconazole resistance, and has comparative clinical efficacy with fluconazole for esophageal candidiasis, while it has relatively low in vitro activity to certain Candida species. There is no comparative study of fluconazole versus micafungin against Candida bloodstream infection.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Shunji Takakura, MD, PhD | +81-75-751-3503 | stakakr@kuhp.kyoto-u.ac.jp |
Contact: Naoko Fujihara, MD | +81-75-751-4237 | fujihara@kuhp.kyoto-u.ac.jp |
Japan | |
Department of Clinical Laboratory Medicine, Kyoto University Hospital | Recruiting |
Kyoto, Japan, 606-8507 | |
Contact: Satoshi Ichiyama, MD, PhD +81-75-751-3502 sichiyam@kuhp.kyoto-u.ac.jp | |
Contact: Yoshitsugu Iinuma, MD, PhD +81-75-751-3476 yiinuma@kuhp.kyoto-u.ac.jp | |
Principal Investigator: Shunji Takakura, MD, PhD |
Study Chair: | Satoshi Ichiyama, MD, PhD | Professor of Medicine, Department of Clinical Laboratory Medicine, Kyoto University Hospital |
Principal Investigator: | Shunji Takakura, MD, PhD | Instructor in Medicine, Department of Clinical Laboratory Medicine, Kyoto University Hospital |
Responsible Party: | Kyoto University Hospital ( Shunji Takakura ) |
Study ID Numbers: | JCRID0502 |
Study First Received: | March 17, 2006 |
Last Updated: | June 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00304772 |
Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Candida bloodstream infection fluconazole micafungin randomized controlled trial |
Fluconazole Mycoses Sepsis Candidiasis Clotrimazole |
Miconazole Tioconazole Torulopsis Micafungin |
Anti-Infective Agents Therapeutic Uses Antifungal Agents Infection Pharmacologic Actions |